Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jun;67(6):975-977.
doi: 10.4103/ijo.IJO_1938_18.

Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema - A case report

Kalpana Babu  1 , Bhagya Sudheer  1 , Anand P Rao  2
Affiliations
Case Reports

Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema - A case report

Kalpana Babu et al. Indian J Ophthalmol. 2019 Jun.

Abstract

A 13-year-old boy with a 4-year history of idiopathic pediatric uveitis and recurrent uveitic macular edema had failed conventional immunomodulatory therapy and presented to us with a vision of 6/24 [right eye (OD)] and 6/9 [left eye (OS)]. Fluorescein angiography showed diffuse vascular leakage along with cystoid macular edema (CME). Intravenous tocilizumab (10 mg/kg body) was given as 14 injections over 12 months. Repeat fluorescein angiography every 3 months showed a dramatic improvement in the vascular leakage and resolution of CME. At 13 months OF follow-up, vision had improved to 6/9p (OD) and 6/6(OS) with no recurrence of inflammation or CME.

Keywords: Biologics; cystoid macular edema; idiopathic; pediatric uveitis; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Fundus photographs of right (a) and left eyes (b) showing vitritis in the right eye with otherwise normal looking posterior pole with corresponding OCTs showing cystoid changes in the fovea in the right (c) and hyperreflective dots in the inner retina in the left eye (d)
Figure 2
Figure 2
Fluorescein angiography showing diffuse vascular leakage, increasing toward the later phases, a hot disc and leakage at the macula suggestive of cystoid macular edema with corresponding indocyanine green angiography of the right (a) and left eyes (b). The ICG pictures are noncontributory
Figure 3
Figure 3
Fluorescein angiography after 3 months of intravenous tocilizumab showing decrease in vascular leakage, resolution of cystoid macular edema and reduced leakage from the optic discs in right (a) and left eyes (b)
Figure 4
Figure 4
Fluorescein angiography at 6 months (a and b) and 13 months (c and d) after initiation of intravenous tocilizumab, showing further decrease in vascular leakage, no cystoid macular edema or leakage from the optic discs in right and left eyes
See this image and copyright information in PMC

References

    1. Lopalco G, Fabiani C, Sota J, Lucherini OM, Tosi GM, Frediani B, et al. IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol. 2017;36:1459–69. - PubMed
    1. Tappeiner C, Mesquida M, Adan A, Anton J, Ramanan AV, Carreno E, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183–8. - PubMed
    1. Mesquida M, Molins B, Llorenc V, Hernandez M, Espinosa G, Sainz de la Maza M, et al. Twenty four month follow-up for tocilizumab therapy for refractory uveitis related macular edema. Retina. 2018;38:1361–70. - PubMed
    1. Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (Month 6) outcomes of the STOP Uveitis study: Evaluating the safety, tolerability and efficacy of tocilizumab in patients with non-infectious uveitis. Am J Opthalmol. 2017;183:71–80. - PubMed
    1. Deuter CME, Zeirhut M, Igney-Oertel A, Xenitidis T, Fedit A, Sobolewska B, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;25:215–20. - PubMed

Publication types

Substances